Patients With IBD at Increased Risk for CVD, Renal Complications After COVID-19
Infection with SARS-CoV-2 has been associated with increased risk for CVD and renal complications.
Infection with SARS-CoV-2 has been associated with increased risk for CVD and renal complications.
Patients with COVID-19 who required low-flow oxygen supplementation were randomly assigned to receive either SNG001 (n=314) or placebo (n=309) once daily for 14 days.
The MVA-BN vaccine, developed by Bavarian Nordic, was evaluated in a clinical trial.
The patient cohorts were well-balanced at baseline, and, overall, 45.4% had a history of biologic therapy failure.
Although ustekinumab is a common therapy used to treat CD, no serum concentrations that associate with outcomes have been established.
The study authors concluded that ESG is safe for patients with class III obesity and its efficacy was comparable to SG and RNYB.
Researchers evaluated the accuracy of the BV score using data from pediatric patients with fever who presented at emergency departments or urgent care centers.
The pooled cohort comprised 854,876 prediabetes cases and 2,190,511 control cases.
Rate of decolonization was highest for patients in the EGD group (85.7%), followed by those in the oral capsule (84.6%), colonoscopy (63.6%), and gastric tube (50%) groups.
During a median follow-up period of 73 (range, 13-111) weeks, 1 patient discontinued treatment with lenacapavir due to grade 1 nodule at the injection site.